Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "Vaccines"

748 News Found

Evonik starts construction of US$220 million lipid innovation center in Lafayette
News | March 31, 2023

Evonik starts construction of US$220 million lipid innovation center in Lafayette

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness


Jubilant receives additional CAD 23.8 million loan facility for CMO Montreal facility
News | March 17, 2023

Jubilant receives additional CAD 23.8 million loan facility for CMO Montreal facility

This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec


Build a sustainable healthcare and lifesciences industry, say Experts
Healthcare | March 11, 2023

Build a sustainable healthcare and lifesciences industry, say Experts

Time to combine innovation, access and technology to deliver positive patient outcomes


ProBioGen’s growth strategy continues successfully
News | March 03, 2023

ProBioGen’s growth strategy continues successfully

Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team


Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Drug Approval | February 23, 2023

Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial


Research underscores Beyfortus’ potential to prevent RSV disease in infants
News | February 23, 2023

Research underscores Beyfortus’ potential to prevent RSV disease in infants

The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile


USFDA accepts for priority review the sNDA for Merck’s Prevymis
Drug Approval | February 18, 2023

USFDA accepts for priority review the sNDA for Merck’s Prevymis

FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients


Biocon Q3 FY23 revenue up 36%
News | February 17, 2023

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses


Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData
News | February 17, 2023

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year


Sanofi announces change in R&D leadership
People | February 14, 2023

Sanofi announces change in R&D leadership

Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim